Answers are grounded in this paper and cite their sources.
Experimental study uncovers potent broadly neutralizing antibodies targeting gp120 in an HIV-1-infected African donor, highlighting a new target for vaccine design.
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals, define critical epitopes for HIV vaccine design. Using a systematic approach, we have examined neutralization breadth in the sera of about 1800 HIV-1-infected individuals, primarily infected with non-clade B viruses, and have selected donors for monoclonal antibody (mAb) generation. We then used a high-throughput neutralization screen of antibody-containing culture supernatants from about 30,000 activated memory B cells from a clade A-infected African donor to isolate two potent mAbs that target a broadly neutralizing epitope. This epitope is preferentially expressed on trimeric Envelope protein and spans conserved regions of variable loops of the gp120 subunit. The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses.
No takes yet. Share an insight, caveat, or question.
Walker et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: